Loading...
•
Sep 30, 2022
Sanara MedTech Q3 2022 Earnings Report
Sanara MedTech reported record revenue driven by increased product recognition and team efforts.
Key Takeaways
Sanara MedTech Inc. announced its third quarter 2022 results, highlighting a record revenue achievement driven by increased product recognition. The company is integrating Scendia Biologics and has formed a new chronic wound care partnership with InfuSystem Holdings, Inc.
Achieved record revenue for the third quarter of 2022.
Revenue record for the historical business before the acquisition of Scendia Biologics.
Integrating Scendia into the Company.
Announced a new chronic wound care partnership with InfuSystem Holdings, Inc.
Forward Guidance
The company looks forward to further integrating Scendia into its business and working with InfuSystem to continue providing solutions that improve outcomes and reduce costs of care.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...